LongBio Pharma (HK:01779): LP-003 Phase III Trial Meets Primary Endpoint in Seasonal Allergic Rhinitis
Jun 12, 2026 06:16
CST Updated
06:38
LongBio
Next-Generation Large Molecule Antibody Developer
Next-Generation Large Molecule Antibody Developer